Medicine and Dentistry
Patient
100%
Ganglioglioma
71%
Glioblastoma
55%
Neoplasm
41%
Therapeutic Procedure
35%
Diagnosis
30%
Bevacizumab
21%
Mutant
21%
Analysis
18%
Oligodendroglioma
18%
Temozolomide
18%
Gadolinium
16%
Overall Survival
16%
Molecular Diagnosis
16%
Cerebrospinal Fluid
14%
Pediatrics
11%
Magnetic Resonance Imaging
11%
Lesion
10%
Tissues
10%
Promoter Region
9%
Surgery
9%
Calcification
9%
Hospital
8%
Woman
8%
Radiation Therapy
8%
Necrosis
8%
High Resolution Melting Analysis
8%
Chemotherapy
8%
Brain Cancer
7%
Pilocytic Astrocytoma
7%
Internal Carotid Artery
7%
Isocitrate Dehydrogenase 1
7%
Anterior Cerebral Artery
7%
Central Nervous System Tumor
7%
Hypovolemia
7%
Arteriovenous Fistula
7%
Congenital Malformation
7%
Craniopharyngioma
7%
Microglia
7%
Bezafibrate
7%
Medical Care
7%
Cell-Free DNA
7%
Survival
6%
Inpatient
6%
Case Report
6%
Symptom
6%
Cells
6%
Age
6%
Combination Therapy
5%
Follow up
5%
Biochemistry, Genetics and Molecular Biology
Mutation
64%
Isocitrate Dehydrogenase
34%
Promoter Region
22%
Overall Survival
20%
Wild Type
16%
Bevacizumab
15%
Mutant
13%
T Cell
12%
Survival
12%
Telomerase Reverse Transcriptase
11%
Methylation
10%
Programmed Cell Death 1
9%
Facilitated Diffusion
8%
Melting Point
7%
Gadolinium
7%
Metabolite
7%
Sample
7%
Association
7%
Bezafibrate
7%
Modifier Gene
7%
Spectroscopy
7%
Phosphorylase
7%
P16
7%
Intravenous Immunoglobulin
7%
Phosphotransferase
7%
Kinase
7%
Cyclin-Dependent Kinase
7%
Classification
5%
Cell Marker
5%
Chromatin
5%
Gene Expression
5%
PD-L1
5%
IDH1
5%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
19%
Malignant Neoplasm
16%
Neoplasm
15%
Bevacizumab
15%
Programmed Cell Death
13%
Programmed Death-Ligand 1
10%
Biological Marker
9%
Brain Cancer
7%
Temozolomide
7%
Isocitrate Dehydrogenase 1
7%
Bezafibrate
7%
Immunotherapy
5%
Non Small Cell Lung Cancer
5%
Nivolumab
5%
Cell Marker
5%
Overall Survival
5%
Survival
5%
Vincristine
5%
Procarbazine
5%